Skip to content

Clinical Manual of Child and Adolescent Psychopharmacology, Third Edition

Edited by Molly McVoy, M.D., and Robert L. Findling, M.D., M.B.A.

  • ISBN 978-1-61537-126-6
  • Item #37126

View Pricing

List Price

APA Members

20% off

APA Resident-Fellow Members

25% off


The new, third edition of the Clinical Manual of Child and Adolescent Psychopharmacology has been thoroughly revised, yet its mission remains the same: to keep clinicians up-to-date on the latest research so that they can provide state-of-the-art care to their young patients. To this end, the book describes and explores those elements that are specific to pediatric psychopharmacology; this defines and positions the volume at the nexus of child and adolescent psychiatry, pediatrics, and pharmacology. A stellar roster of contributors addresses new treatments for youths with disruptive behavior disorders, mood disorders, anxiety disorders, pervasive developmental disorders, and psychotic illnesses and tackles some of the most important emerging issues in the field. For example, advances in understanding the long-term treatment effects of medications in pediatric populations are thoroughly reviewed, including not only maintenance studies that consider the durability of efficacy but also clinical trials of greater duration designed to specifically evaluate long-term safety. In addition, recent studies of combination therapies are examined, helping clinicians better understand how to treat the complicated patients that arrive every day at a prescribing clinician's office. Finally, because research designs now include a broader base of patient populations to make the data more applicable to everyday clinical practice, the book focuses on head-to-head studies with multiple active comparators.

The book offers clinicians comprehensive, accessible information and boasts a multitude of helpful features:

  • The book is organized by diagnosis instead of agent class. This makes it a true clinical desktop reference that allows clinicians to quickly and efficiently search treatment options and the evidence base on a case-by-case basis. DSM-5 criteria and information on comorbidities are also included.
  • The American Academy of Child and Adolescent Psychiatry Practice Parameters are integrated into the discussion, where applicable, in support of standard of care.
  • The book has been updated to include the latest research at the time of publication.
  • A new chapter has been added to address eating disorders, an area where psychopharmacological research that may apply to children and adolescents is now being pursued.
  • Useful features to help the reader understand and retain the material include clinical summary points, easy to read tables, and current and carefully vetted references.

The Clinical Manual of Child and Adolescent Psychopharmacology, Third Edition, is an indispensable guide to the substantive research that has been done in nearly every area of pediatric psychopharmacology, as well as the major improvements that have been made to the evidence-based practice of treating youths with psychiatric illness.


  • Chapter 1. Developmental Aspects of Pediatric Psychopharmacology
  • Chapter 2. Attention-Deficit/ Hyperactivity Disorder
  • Chapter 3. Disruptive Behavior Disorders and Aggression
  • Chapter 4. Anxiety Disorders
  • Chapter 5. Major Depressive Disorder
  • Chapter 6. Bipolar Disorders
  • Chapter 7. Autism Spectrum Disorder
  • Chapter 8. Tic Disorders
  • Chapter 9. Early-Onset Schizophrenia and Psychotic Illnesses
  • Chapter 10. Eating Disorders


    Nasreen Akbar, M.D.
    Jaina Amin, M.D.
    Boris Birmaher, M.D.
    Dylan A. Braun, B.S.
    Kirsten Craddock, B.A.
    Natoshia Raishevich Cunningham, Ph.D.
    Christopher N. David, B.A.
    David I. Driver, M.D.
    Scott Falkowitz, D.O.
    Nitin Gogtay, M.D.
    Pablo H. Goldberg, M.D.
    Laurence Greenhill, M.D.
    Peter S. Jensen, M.D.
    Christopher J. Keary, M.D
    Jess Levy, M.D.
    Sarah Lytle, M.D.
    Christopher J. McDougle, M.D.
    Michelle L. Palumbo, M.D.
    Elizabeth Pappadopulos, Ph.D.
    Stephanie Pope, M.D.
    Judith L. Rapoport, M.D.
    Moira A. Rynn, M.D.
    Lawrence Scahill, M.S.N., Ph.D.
    Griffin Stout, M.D.
    Tiffany Thomas-Lakia, M.D.
    Benedetto Vitiello, M.D.
    Paula K. Yanes-Lukin, Ph.D.
    Solomon G. Zaraa, D.O.

About the Authors

Molly McVoy, M.D., is Assistant Professor and Training Director in the Division of Child and Adolescent Psychiatry at the University Hospital Case Medical Center, and Research physician at the Discovery and Wellness Center for Children, Case Western Reserve University School of Medicine in Cleveland, Ohio.

Robert L. Findling, M.D., M.B.A., is Director of the Division of Child and Adolescent Psychiatry and Vice Chair of the Department of Psychiatry and Behavioral Sciences at Johns Hopkins Hospital in Baltimore, Maryland.

This new edition is exactly what clinicians need to keep up-to-date on the rapid progress in research on the use of medications to address emotional and behavioral symptoms in children and adolescents. McVoy, Findling, and many expert authors have fully updated the content to enhance evidence-based practice, including both positive and possible negative effects of medications. This book should be on the shelf of every fellow and practitioner in child and adolescent psychiatry, pediatrician, family physician, psychiatric advanced practice nurse, and general psychiatrist who treats children and adolescents. Social workers, psychologists, special education professionals, and those who direct programs in child welfare or juvenile justice will also find important information here.—Mina K. Dulcan, M.D., Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine

One of the biggest strengths of this book is the thorough discussion of research evidence for the use of various psychotropic medications in youth. Readers will become familiar with some of the landmark trials in child and adolescent psychiatry that led to the FDA approval of several medications. Some clinicians may nd it helpful to share the data with certain patients and their families as they are obtaining informed consent for a particular medication. In addition to discussing the rst-line treatment options for all of the disorders, the authors also include secondline and third-line options that have been used clinically to treat a particular disorder and summarize the evidence for those treatments.—Anuja S. Mehta, M.D., Assistant Professor of Psychiatry in the Clinical Sciences Department, University of Central Florida College of Medicine, Orlando, FL, Journal of Psychiatric Practice Vol. 24, No. 1, 01/01/2018

McVoy and Findling's Clinical Manual of Child and Adolescent Psychopharmacology effectively presents our current evidence base; it is an invaluable resource for physicians and other licensed prescribers who are striving to practice rational psychopharmacology for children and adolescents. It is my go-to resource for developing psychopharmacology handouts for trainees, supplemented by literature reviews of the intervening few years since its creation. It accomplishes providing comprehensive summaries while remaining succinct and easy to read. Although it is not a manual of drug metabolism and how pharmacokinetics affects clinical practice—for that, I strongly recommend Carlat's Drug Metabolism in Psychiatry: A Clinical Guide by Daniel J. Carlat—this book is excellent for understanding the clinical research base for the medications we use in practice.—Sibel Algon, M.D., Dr. Algon is with Emma Pendleton Bradley Hospital, East Providence, RI., Journal of the American Academy of Child & Adolescent Psychiatry-Vol 57/ Number 8, 08/01/2018

Related Products

Become an APA Member
Join Now